DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+33.56%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.42B
AUM Growth
+$5.42B
(+19%)
Cap. Flow
+$277M
Cap. Flow
% of AUM
5.11%
Top 10 Holdings %
Top 10 Hldgs %
57.84%
Holding
242
New
154
Increased
21
Reduced
12
Closed
14
Top Buys
| 1 |
Oscar Health
OSCR
|
$103M |
| 2 |
Baxter International
BAX
|
$52.5M |
| 3 |
Revolution Medicines
RVMD
|
$38.4M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$36.7M |
| 5 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$34.4M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$41.2M |
| 2 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$38.5M |
| 3 |
Merus
MRUS
|
$23.6M |
| 4 |
Owens & Minor
OMI
|
$23.2M |
| 5 |
Roivant Sciences
ROIV
|
$18.7M |
Sector Composition
| 1 | Healthcare | 78.16% |
| 2 | Technology | 0.1% |
| 3 | Industrials | 0.09% |
| 4 | Consumer Discretionary | 0.08% |
| 5 | Consumer Staples | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cabaletta Bio
CABA
$133M
| $45.6M | 0.84% |
2,007,729
-332,389
| -14% | -$7.55M |
|
27
Edgewise Therapeutics
EWTX
$1.51B
| $43M | 0.79% |
3,933,137
| – | – |
|
28
Insulet
PODD
$23.9B
| $38.8M | 0.72% |
178,920
+51,920
| +41% | +$11.3M |
|
29
Structure Therapeutics
GPCR
$1.11B
| $33.5M | 0.62% |
822,813
+195,000
| +31% | +$7.95M |
|
30
Alignment Healthcare
ALHC
$3.24B
| $30M | 0.55% |
3,488,808
+741,793
| +27% | +$6.39M |
|
31
DocGo
DCGO
$153M
| $29.7M | 0.55% |
5,320,139
+556,139
| +12% | +$3.11M |
|
32
BioCryst Pharmaceuticals
BCRX
$1.74B
| $27.2M | 0.5% |
4,539,525
+1,253,525
| +38% | +$7.51M |
|
33
Disc Medicine
IRON
$2.07B
| $26.8M | 0.5% |
464,292
+34,292
| +8% | +$1.98M |
|
34
Embecta
EMBC
$847M
| $26.2M | 0.48% |
+1,384,839
| New | +$26.2M |
|
35
Day One Biopharmaceuticals
DAWN
$769M
| $25.7M | 0.47% |
1,761,178
+491,186
| +39% | +$7.17M |
|
36
QuidelOrtho
QDEL
$1.95B
| $25.6M | 0.47% |
348,000
+198,000
| +132% | +$14.6M |
|
37
Galapagos
GLPG
$2.07B
| $25.3M | 0.47% |
+622,112
| New | +$25.3M |
|
38
Viking Therapeutics
VKTX
$3.04B
| $23.8M | 0.44% |
1,279,000
| – | – |
|
39
Pharvaris
PHVS
$1.39B
| $22.8M | 0.42% |
+812,236
| New | +$22.8M |
|
40
Nkarta
NKTX
$151M
| $22.4M | 0.41% |
+3,400,000
| New | +$22.4M |
|
41
Guardant Health
GH
$8.41B
| $21.4M | 0.4% |
791,735
-538,200
| -40% | -$14.6M |
|
42
Castle Biosciences
CSTL
$696M
| $20.8M | 0.38% |
965,428
+18,808
| +2% | +$406K |
|
43
Prelude Therapeutics
PRLD
$68.5M
| $17.6M | 0.33% |
+4,133,000
| New | +$17.6M |
|
44
Replimune Group
REPL
$422M
| $15.3M | 0.28% |
+1,811,710
| New | +$15.3M |
|
45
Tango Therapeutics
TNGX
$747M
| $15.2M | 0.28% |
1,540,000
+746,271
| +94% | +$7.39M |
|
46
Verastem
VSTM
$569M
| $12.5M | 0.23% |
1,538,461
| – | – |
|
47
Alector
ALEC
$238M
| $8.52M | 0.16% |
1,067,810
+12,618
| +1% | +$101K |
|
48
iTeos Therapeutics
ITOS
| $7.92M | 0.15% |
723,000
| – | – |
|
|
CMAX
49
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $7.91M | 0.15% |
15,873,213
| – | – |
|
50
Prime Medicine
PRME
$578M
| $7.84M | 0.14% |
885,314
| – | – |
|